In a previous study we showed that the disposition of clozapine after a single oral dose is unrelated to either debrisoquine or S-mephenytoin hydroxylation polymorphism. The same 14 healthy subjects studied in that investigation were given 150 mg of caffeine. The reciprocal of plasma clozapine AUC (0,24), was correlated with an index of the N3-demethylation of caffeine (r, = 0.84; P = 0.0024), used as a measure of cytochrome P4501A2 (CYP1A2) activity. Ni-and N7-demethylation indices of caffeine also reflect CYP1A2 activity and were also correlated with clozapine clearance (rs = 0.89 and 0.85; P = 0.0013 and 0.0023; respectively). No significant relationships with xanthine oxidase and N-acetyl transferase activity, also assessed by a caffeine test, were found. This study suggests that clozapine is metabolised by CYP1A2 to a major extent.
Introduction
Clozapine is an atypical neuroleptic with potent antipsychotic efficacy and few parkinsonian side-effects, but is associated with a high incidence of agranulocytosis [1] . Classical neuroleptics such as perphenazine [2] , zuclopenthixol [3] , thioridazine [4] and haloperidol [5] are metabolised by the polymorphic debrisoquine hydroxylase, CYP2D6 [6] . However, clozapine, which is also eliminated by oxidative metabolism, shows similar disposition in extensive (EM) and poor (PM) metabolisers of debrisoquine [7] .
Recently, Jerling et al. [8] found that the plasma concentration of clozapine increased markedly in patients who also received fluvoxamine. A similar interaction between tricyclic antidepressants and fluvoxamine has been demonstrated [9, 10] . Spina et al. [11] showed that fluvoxamine markedly inhibited the N-demethylation of imipramine without affecting the CYP2D6 mediated hydroxylation of desipramine [12] . Br0sen et al. [13] have shown in vitro that fluvoxamine is a potent inhibitor of phenacetin O-deethylation, a reaction catalysed by CYP1A2.
The major metabolic pathway of caffeine is N-3-demethylation, which is mainly mediated by CYP1A2 [14, 15] . The N-1 and N-7-demethylations are catalysed to a small extent by CYP2E1 in addition to CYP1A2 [14, 16] . The polymorphic N-acetyl transferase and xanthine oxidase are involved in the further metabolism of caffeine [14, 15] . Caffeine may thus be used as a probe drug for several drug metabolising enzymes. In the present study we performed a caffeine test in subjects previously investigated with respect to clozapine disposition [7] .
Methods
In a previous study [7] Fourteen of the 15 healthy Swedish subjects studied [7] took part in the present study, which was conducted 1 AAMU: 5-acetylamino-6-amino-3-methyluracil; 7X: 7-methylxanthine; 1U: 1-methyl uric acid; 3X: 3-methylxanthine; 37U: 3,7-dimethyl uric acid; IX: 1-methylxanthine; 13U: 1,3-dimethyl uric acid; 37X: 3,7-dimethylxanthine (theobromine); 17U: 1,7-dimethyl uric acid; 17X: 1,7-dimethylxanthine (paraxanthine); 13X: 1,3-dimethylxanthine (theophylline); 137X: 1,3,7-trimethylxanthine (caffeine).
Results
All subjects tolerated the 48 h abstinence from caffeine containing food and beverage, although some subjects had headache. The reciprocal of plasma AUC (0,24) of clozapine [7] correlated with measures of caffeine Ni-, 3-and 7-demethylations (rs = 0.89, 0.84 and 0.85; all P < 0.01) ( Table 1) . The relationship with N3-demethylation is shown in Figure 1 The only smoker participating in this study had the highest N3-demethylation index and the third highest reciprocal clozapine AUC (0,24) value.
Discussion
The pharmacokinetic interaction observed in patients between fluvoxamine and clozapine [8] suggests that clozapine might be metabolised by CYP1A2, since fluvoxamine was shown to be a potent inhibitor of this isoform of cytochrome P450 in vitro [13] . In the present study about 70% of the variance in the oral clearance of clozapine was accounted for by an index of caffeine N3-demethylation, used as an in vivo marker of CYPlA2 activity. This suggests that clozapine is to a major extent metabolized by CYP1A2, and is consistent with the knowledge that both clozapine disposition [17] and CYP1A2 activity [14, 15] are inducible by smoking. The only smoker Table 1 in this study had the highest index of CYP1A2 activity and a high oral clearance of clozapine. Jerling et al. [8] showed that carbamazepine decreases plasma concentrations of clozapine in patients given both drugs. Carbamazepine is an inducer of CYP3A4 and this enzyme may metabolise clozapine in addition to CYP1A2. Carbamazepine is not an inducer of caffeine metabolism [18] and, therefore, not an inducer of CYP1A2. Several neuroleptics are metabolised by CYP2D6 and pharmacokinetic interactions have been reported with drugs metabolised by this enzyme including neuroleptics and tricyclic antidepressants [6] . However, measurement of plasma concentrations of clozapine in psychiatric patients indicated no interaction between clozapine and other neuroleptics or tricyclic antidepressants metabolised by CYP2D6 [8] . In theory, the metabolism of clozapine may be inhibited by several drugs metabolised by CYP1A2, such as imipramine, phenacetin, theophylline and possibly caffeine.
